Dr Gayle van der Kraaij (Amsterdam UMC, the Netherlands) presented the first-year results from a Dutch/Belgian study that showed increased efficacy, adalimumab serum levels, and fewer antidrug antibodies when adalimumab is supplemented with methotrexate .
She explained the problem: adalimumab therapy is hampered by primary and secondary non-response. The lack of response is because in many patients only low serum drug levels can be detected, which is directly attributable to the formation of antidrug antibodies. The researchers sought to optimise adalimumab efficacy by applying a trick learned from rheumatoid arthritis, namely that the addition of methotrexate can alleviate this problem. The investigators performed a pragmatic randomised controlled trial in psoriasis patients, which was assessor-blinded in 5 hospitals in the Netherlands and Belgium. They compared adalimumab (n=30) vs adalimumab with methotrexate (10 mg/week supplemented with folic acid;...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis Next Article
Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies »
Table of Contents: SPIN 2019
Aetiology: Triggers and Risk Factors
Advances in Therapy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.